Article citationsMore>>

Lam, A.M., Espiritu, C., Bansal, S., Micolochick Steuer, H.M., Niu, C., Zennou, V., Keilman, M., Zhu, Y., Lan, S., Otto, M.J. and Furman, P.A. (2012) Genotype and Subtype Profiling of PSI-7977 as a Nu-cleotide Inhibitor of Hepatitis C Virus. Antimicrobial Agents and Chemotherapy, 56, 3359-3368.
https://doi.org/10.1128/AAC.00054-12

has been cited by the following article:

• TITLE: Response of HCV Yemeni Patients to Sofosbuvir/Ledipasvir in Combination with Ribavirin

  AUTHORS: Abdulgafoor Kassim, Ramea Alathwary, Talal Al-hogami

  KEYWORDS: HCV, Early Virological Response (EVR), MPIVIROPACT Plus, Yemen

  JOURNAL NAME: Open Access Library Journal, Vol.6 No.6, June 28, 2019

  ABSTRACT: Objectives: To study the effectiveness and safety of ledipasvir-sofosbuvir plus ribavirin treatment in Yemeni patient with HCV infection. Design: Prospective study of sixty-five Yemeni patients confirmed with HCV infection during the period from January 2017 to April 2018. Setting: Gastrointestinal and liver diseases specialized center in Ibb city, Yemen. Subjects: Patients with proved HCV infection by PCR. Results: We collected 65 cases with HCV infection. They were 19 (29.2%) males and 46 (70.8) females with age ranged between 18 years and 70 years and the mean age was 47.98 ± 11.90 years. sixteen (24.6%) of them had compensated liver cirrhosis and the remainder were non-cirrhotic healthy individual. The early virological response reported in 100% of cases while the sustained virological response (SVR) reported in 90.8%. The reported side effects of our patients were fatigue in (24.6%), abdominal pain in (13.8%), diarrhea in (10.8%), insomnia in (9.2%), headache in (7.7%), and nausea/vomiting in (7.7%). Conclusion: The Sofosbuvir-ledipasvir plus Ribavirin treatment was highly effective and safe for the treatment of hepatitis C patients in Yemen.